Orphan NLP Target high-need CNS and oncology franchises with Relmada's NDV-01 and sepranolone programs, highlighting Phase 2 readiness and potential for accelerated access in urology, bladder cancer, Tourette’s syndrome, Prader-Willi syndrome, and related compulsive disorders.

Strategic Advisory Leverage recent senior advisory hires, including Michael Quirk and other neuroscience drug discovery leaders, to build credibility with co-development partners, contract research organizations, and potential licensing collaborators.

Funding Momentum Capitalize on ongoing and recent financing activity to support out-licensing, co-development deals, or strategic partnerships for late-stage progression, emphasizing capital flexibility and pipeline momentum post-REL-1017 transition.

Clinical Collaboration Engage with urology and oncology thought leaders and conferences where NDV-01 and bladder cancer programs are featured, aligning sponsor opportunities with AUA2026 activities and related clinical forums.

Global Reach Position Relmada as a gateway for international CROs and pharma partners seeking CNS and oncology breakthroughs, using the company’s private placement history and scalable technology stack as a proof point for rapid collaboration and project execution.